Company Overview

Kite Pharma (formerly known as Arcellx) was founded by David Hilbert, a serial entrepreneur and former Vice President at Human Genome Sciences. The company developed next-generation CAR-T cell therapies to treat multiple myeloma with greater efficacy and durability than current treatments. Early clinical success led to a co-development partnership with Kite Pharma in Frederick, Maryland, and ultimately to Kite Pharma’s $7.8 billion acquisition by Gilead Sciences, a deal that bolstered Gilead’s CAR-T cell therapy pipeline.

Kite Pharma’s growth trajectory reflects the broader arc of Maryland’s biotech corridor: the company started at the Germantown Innovation Center, scaled into space at West Watkins Mill, and identified its headquarters at 800 King Farm in Rockville, anchoring itself in the heart of the Biotech Corridor before catching the attention of one of the world’s largest biopharmaceutical companies.

The Challenge

As Kite Pharma moved from incubator space to a purpose-built facility, it needed more than an available building; it needed a conventional office asset transformed into a functional wet lab and R&D space. The company required a resource partner who could navigate City planning and zoning processes for a complex lab conversion project, coordinate directly with its outside project management team, and help the company build visibility and relationships within Rockville’s life sciences ecosystem as a newcomer to the City.

REDI’s Approach

Site Identification. REDI worked alongside Scheer Partners, Kite Pharma’s broker, to identify the company’s headquarters location at 800 King Farm in Rockville, matching the company’s growth-stage needs with a building suited for repositioning into lab and R&D use.

City Services Connections. REDI connected Kite Pharma with key City services, including direct lines to the Planning Department, helping the company and building owner navigate Rockville’s processes as it prepared to reposition an office building for lab and operational use.

Project Coordination. REDI organized and facilitated meetings between the City of Rockville and Facility Logix, the project management firm supporting Kite Pharma’s build-out, ensuring alignment between the company’s project team and City stakeholders throughout the repositioning process.

Zoning & Code Compliance Support. REDI provided support around zoning and code compliance considerations tied to the repositioning project, helping smooth the path for a life sciences use in a previously conventional office building.

Building Repositioning. 800 King Farm underwent a substantial transformation to support Kite Pharma’s wet lab needs. Upgrades included new HVAC systems suited for lab operations, a full reskinning of the building’s interior and common spaces, and an owner-built incubator lab space, repositioning the building from a conventional office asset into a true R&D facility with wet lab capabilities.

Elected Official Engagement. REDI organized site tours for elected officials at the state, county, and City of Rockville levels, giving Kite Pharma’s visibility with the policymakers who shape the region’s life sciences investment climate and creating opportunities for the company to showcase its work directly to decision-makers.

Marketing & Ecosystem Integration. REDI promoted Kite Pharma through its marketing channels and local industry events, helping integrate the company into Rockville’s broader life sciences ecosystem and raising its profile among peer companies, partners, and prospective talent in the corridor.

The Gilead Acquisition: A Rockville Company on the National Stage

Kite Pharma’s establishment at 800 King Farm positioned the company for its next major milestone: a $7.8 billion acquisition by Gilead Sciences to strengthen Gilead’s CAR-T cell therapy pipeline. The deal is part of a broader wave of consolidation sweeping the global life sciences industry, as large, well-capitalized pharmaceutical companies pursue high-impact acquisitions of differentiated platforms to replace revenue at risk from expiring drug patents. That a Rockville-headquartered company was the target of one of this cycle’s most notable CAR-T deals is a direct signal of the caliber of science being built locally and of the role REDI’s site selection and repositioning support played in giving Kite Pharma a real, functioning R&D home base from which to reach that milestone.

Why It Matters

Kite Pharma’s path from the Germantown Innovation Center, to West Watkins Mill, to a fully repositioned wet lab headquarters at 800 King Farm, to a $7.8 billion acquisition by Gilead Sciences mirrors the trajectory REDI aims to support: helping high-potential Maryland life sciences companies scale in place and build enough value to compete on the national stage. Rockville is considered the epicenter of life science activity within Montgomery County and the broader DC-MD-VA region, a market nationally ranked #3 as a top life science hub. Throughout the project, REDI worked alongside external partners including Scheer Partners and Banyan Street Capital, owners of 800 King Farm, to advocate for repositioning existing office space into wet lab space at a time when new lab inventory is badly needed across the region.

As the life sciences industry continues to see a wave of mergers and acquisitions worldwide, Kite Pharma’s acquisition underscores what’s at stake for Rockville: the City has proven it can attract, house, and grow the kind of company that draws acquisition interest from major global biopharma players. That reputation strengthens Rockville’s hand in recruiting the next generation of life sciences companies, even as consolidation reshapes ownership and employment within the sector. The 800 King Farm project itself remains a template for the City and proof that Rockville can convert underutilized office stock into competitive wet lab and R&D space, a capability that matters as the City competes for lab-dependent tenants across the Biotech Corridor and works to keep the value created by companies like Kite Pharma rooted in the local market.